Key Points – Bioventus reported solid second-quarter results, with revenue up 4% to $153 million, adjusted EBITDA rising to $35 million and adjusted EPS increasing to $0.22.
The company reaffirmed its 2026 guidance for $600 million–$610 million in revenue and $0.75–$0.79 in adjusted EPS. – Pain Treatments led performance, growing 12% to $82 million on strong demand for DUROLANE
Management also expects accelerating contributions from platelet-rich plasma, peripheral nerve stimulation and Ultrasonics during the second half. – The board formed an independent committee to review strategic alternatives after receiving acquisition interest, including an unsolicited proposal; options may include a sale or continued standalone execution. Bioventus also reduced debt by $24 million during the quarter, lowering net leverage below 2 times. Bioventus (NASDAQ:BVS) reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.
The company also said its board formed a committee of independent directors to evaluate strategic options after receiving multiple expressions of interest and an unsolicited acquisition proposal. President and CEO Rob Claypoole said the alternatives could include a sale of the company or continued execution of Bioventus’ standalone plan. The committee is being advised by Evercore. “We have built a strong foundation for growth and success at Bioventus,” Claypoole said, adding that the committee would evaluate options intended to maximize shareholder value.